Outside Bar (Bearish)
|Bid||2.2000 x 2900|
|Ask||2.2400 x 1400|
|Day's Range||2.1900 - 2.2700|
|52 Week Range||1.5550 - 4.2800|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for LIFELearn more
Investing.com -- Here is your weekly Pro Recap preview of key biotech and FDA catalysts to look out for in the next week: Sana Biotech, aTyr Pharma, and Theseus Pharma are set to share new data, and the FDA is set to review a Lexicon Pharma compound.
Potential aTyr Pharma, Inc. ( NASDAQ:LIFE ) shareholders may wish to note that the Independent Director, Paul Schimmel...
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 25.64% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
If you are only concerned about upside potential, looking into some stocks and cryptos with high returns is the way to go. The current environment is indeed very risky, with a recent rate hike and a recession on the horizon. Still, there are high-risk, high-return assets that can deliver multibagger gains if you’re lucky. However, I would note that chasing high upside potential comes with a lot of risks as you’d have to step foot into speculative territory. But the rewards can be just as rewardi
Any investor seeking growth stocks that are poised to triple in 2023 will need a strong appetite for risk. That much is very clear. Those same investors should also be well aware that they’ll be investing in cheaper stocks generally. Lower-priced shares have greater potential to multiply in value. That means investors looking for three-baggers will be looking at penny stocks which are, again, risky. Okay, you get it, to triple one’s capital in less than a year requires significant risk. However,
Penny stocks are controversial, to say the least. When it comes to these under $5 per share investment opportunities, Wall Street observers usually either love them or hate them. The penny stock-averse point out that while the bargain price tag is tempting, there could be a reason shares are trading at such low levels like poor fundamentals or insurmountable headwinds. However, the other side of the coin has merit as well. Naturally, with these cheap tickers, you get more bang for your buck in t
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
To get a sense of who is truly in control of aTyr Pharma, Inc. ( NASDAQ:LIFE ), it is important to understand the...
aTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2022 Earnings Call Transcript November 10, 2022 aTyr Pharma, Inc. reports earnings inline with expectations. Reported EPS is $-0.46 EPS, expectations were $-0.46. Operator: Good afternoon, ladies and gentlemen and welcome to aTyr Pharma’s Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. Later, […]
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Quite a few insiders have dramatically grown their holdings in aTyr Pharma, Inc. ( NASDAQ:LIFE ) over the past 12...